Variants of HCMV UL18 Sequenced Directly from Clinical Specimens Associate with Antibody and T-Cell Responses to HCMV

Int J Mol Sci. 2022 Oct 26;23(21):12911. doi: 10.3390/ijms232112911.

Abstract

Around 80% of adults worldwide carry human cytomegaloviris (HCMV). The HCMV gene UL18 is a homolog of HLA class I genes and encodes a protein with high affinity for the NK and T-cell cytotoxicity inhibitor LIR-1. UL18 was deep sequenced from blood, saliva or urine from Indonesian people with HIV (PWH) (n = 28), Australian renal transplant recipients (RTR) (n = 21), healthy adults (n = 7) and neonates (n = 4). 95% of samples contained more than one variant of HCMV UL18, as defined by carriage of nonsynonymous variations. When aligned with immunological markers of the host's burden of HCMV, the S318N variation associated with high levels of antibody reactive with HCMV lysate in PWH over 12 months on antiretroviral therapy. The A107T variation associated with HCMV antibody levels and inflammatory biomarkers in PWH at early timepoints. Variants D32G, D248N, V250A and E252D aligned with elevated HCMV antibody levels in RTR, while M191K, E196Q and F165L were associated with HCMV-reactive T-cells and proportions of Vδ2- γδ T-cells-populations linked with high burdens of HCMV. We conclude that UL18 is a highly variable gene, where variation may alter the persistent burden of HCMV and/or the host response to that burden.

Keywords: UL18; cytomegalovirus; deep sequencing; people with HIV; renal transplant recipients.

MeSH terms

  • Adult
  • Australia
  • Base Sequence
  • Capsid Proteins / genetics
  • Cytomegalovirus*
  • Humans
  • Immunoglobulins / metabolism
  • Infant, Newborn
  • T-Lymphocytes*

Substances

  • Capsid Proteins
  • Immunoglobulins

Grants and funding

This study of RTR was funded by the National Health and Medical Research Council of Australia (Grant ID 1068652) and by Curtin University. The Indonesian HIV study was funded in part by Universitas Indonesia. S.W. received an Australian Government Research Training Program Scholarship. The Curtin Health Innovation Research Institute provided technology platforms.